Skip to main content

Kenvue Inc.

corporate_fare Company Profile

Kenvue Inc.

KVUE·NYSE·Life Sciences·CIK 0001944048

Kenvue is a global leader in consumer health, operating at the intersection of healthcare and consumer goods. The company is the world's largest pure-play consumer health company by revenue, with $15.1 billion in Net sales in the fiscal year 2025. Kenvue combines science, consumer insights, and a digital strategy to help consumers live healthier lives. Its portfolio of brands, built on over a century of heritage, includes Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena®, Nicorette®, Tylenol®, and Zyrtec®. These brands are backed by science and recommended by healthcare professionals. Kenvue's product portfolio is divided into three segments: Self Care, Skin Health and Beauty, and Essential Health products. The company markets its products across more than 165 countries worldwide, reaching consumers in North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM). Kenvue's global scale and broad brand portfolio are supported by its capabilities and digital strategy, enabling it to respond to trends in its categories and geographic markets. The marketing organization uses precision marketing, e-commerce, and digital capabilities to develop consumer insights and enhance brand relevance. The research and development organization combines these insights with scientific expertise and engagement with healthcare professionals to drive innovative new products and solutions centered on consumer health.

Kenvue Inc. (NYSE:KVUE) is a publicly traded company in the Life Sciences sector. Wiseek monitors KVUE SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Kimberly-Clark Details Kenvue Acquisition Rationale, Synergies, and Combined Financial Outlook
  • Kenvue and Kimberly-Clark Highlight $7B+ U.S. Investment Post-Merger in New Advertisements

Financial Snapshot

Fiscal year ended December 28, 2025
Revenue
$15.12B
Net Income
$1.47B
Diluted EPS
$0.76
Op. Cash Flow
$2.2B
Free Cash Flow
$1.72B
Gross Profit
$8.79B
Operating Income
$2.41B
Cash & Equivalents
$1.06B
Total Debt
$750M
Debt / Equity
0.07×
Net Margin
9.7%
Shares Outstanding
1.92B sh
Source: 10-K · filed 2026-02-20 · accession 0001944048-26-000030
$19.78 +0.03% today
52-week range · as of 2026-05-07 $14.02 – $25.17
Market cap
$37.92B
Volume
19.6M (1.0× avg)
3-mo avg 20.1M
Live data · 2026-07-29 10:31 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed KVUE - Filings & News (Page 2)

KVUE
Jan 08, 2026, 4:30 PM EST
Filing Type: 425
Importance Score:
9
Price at Filing: $16.99
Real-time Price: $19.78 info
Change: +$2.79 (+16%) info
Market Cap: $37.92B info
KVUE
Jan 07, 2026, 5:15 PM EST
Filing Type: 425
Importance Score:
8
Price at Filing: $16.69
Real-time Price: $19.78 info
Change: +$3.09 (+19%) info
Market Cap: $37.92B info